# Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Study · id `cardio:ct-nct05767346` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05767346](<https://clinicaltrials.gov/study/NCT05767346>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05767346

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.

## Technical summary

Registry record NCT05767346. Randomized; triple masking; primary purpose treatment. Start 2023-06-20 (actual); primary completion 2025-02-28 (actual). Results posted on 2026-06-09.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 175 participants (enrolled count; ClinicalTrials.gov record NCT05767346, source copy `cardio:ctgov-nct05767346-2026-06-09`, retrieved 2026-10-31)
- Started: 2023-06-20 (actual) (ClinicalTrials.gov record NCT05767346, source copy `cardio:ctgov-nct05767346-2026-06-09`, retrieved 2026-10-31)
- Primary completion: 2025-02-28 (actual) (ClinicalTrials.gov record NCT05767346, source copy `cardio:ctgov-nct05767346-2026-06-09`, retrieved 2026-10-31)
- Completion: 2025-03-28 (actual) (ClinicalTrials.gov record NCT05767346, source copy `cardio:ctgov-nct05767346-2026-06-09`, retrieved 2026-10-31)
- Results first posted: 2026-06-09 (ClinicalTrials.gov record NCT05767346, source copy `cardio:ctgov-nct05767346-2026-06-09`, retrieved 2026-10-31)
- Countries: United States; Brazil; Canada; China; Denmark; France; Germany; Hungary; Israel; Italy; Netherlands; Spain; United Kingdom (ClinicalTrials.gov record NCT05767346, source copy `cardio:ctgov-nct05767346-2026-06-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05767346-2026-06-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
- Acronym: MAPLE-HCM
- Condition: Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Intervention (Drug): Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
- Intervention (Drug): Placebo to match aficamten
- Intervention (Drug): Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
- Intervention (Drug): Placebo to match metoprolol succinate
- Lead sponsor: Cytokinetics
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Cytokinetics (`cardio:org-cytokinetics`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy (`cardio:pubmed-40888697`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM (`cardio:pubmed-40932433`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial (`cardio:pubmed-41348072`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy (`cardio:pubmed-41493295`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial (`cardio:pubmed-42307914`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 8ae7b46dc80b651c628ee44da6ed1e01256ee5805f17edb13c746d521308256f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
